Schonfeld Strategic Advisors LLC Adverum Biotechnologies, Inc. Transaction History

Schonfeld Strategic Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.54 - $10.3 $15,552 - $296,640	-28,800 Reduced 48.0%	31,200 $18,000
Q1 2022 May 16, 2022	BUY	$1.23 - $1.95 $73,800 - $117,000	60,000 New	60,000 $79,000
Q4 2020 Feb 16, 2021	SELL	$9.84 - $14.26 $1.4 Million - $2.03 Million	-142,295 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$10.3 - $21.64 $888,869 - $1.87 Million	86,298 Added 154.11%	142,295 $1,000
Q2 2020 Aug 14, 2020	BUY	$8.53 - $25.64 $375,823 - $1.13 Million	44,059 Added 369.07%	55,997 $1.17 Million
Q1 2020 May 15, 2020	SELL	$7.98 - $16.32 $695,480 - $1.42 Million	-87,153 Reduced 87.95%	11,938 $117,000
Q4 2019 Feb 14, 2020	SELL	$5.12 - $12.22 $3.01 Million - $7.18 Million	-587,609 Reduced 85.57%	99,091 $1.14 Million
Q3 2019 Nov 14, 2019	BUY	$5.24 - $15.89 $3.6 Million - $10.9 Million	686,700 New	686,700 $3.74 Million

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.